Genfit
22
1
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
22.7%
5 terminated/withdrawn out of 22 trials
76.2%
-10.3% vs industry average
5%
1 trials in Phase 3/4
25%
4 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Role: lead
Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
Role: lead
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
Role: lead
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
Role: lead
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Role: lead
Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects
Role: lead
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Role: lead
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Role: lead
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
Role: lead
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
Role: lead
Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin
Role: lead
Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers
Role: lead
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
Role: lead
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
Role: lead
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Role: lead
Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers
Role: lead
Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers
Role: lead
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
Role: lead
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
Role: lead
Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus
Role: lead